|
US6090406A
(en)
*
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
|
US5916588A
(en)
*
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
|
CA1267087A
(en)
*
|
1985-02-14 |
1990-03-27 |
Nicolaas Visser |
Synthetic immunogen
|
|
DE3601136A1
(de)
*
|
1986-01-16 |
1987-07-23 |
Max Planck Gesellschaft |
Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
|
|
US4803070A
(en)
*
|
1986-04-15 |
1989-02-07 |
Ribi Immunochem Research Inc. |
Immunological emulsion adjuvants for polysaccharide vaccines
|
|
US5554372A
(en)
*
|
1986-09-22 |
1996-09-10 |
Emory University |
Methods and vaccines comprising surface-active copolymers
|
|
US6222020B1
(en)
*
|
1987-01-07 |
2001-04-24 |
Imperial Cancer Research Technology Limited |
Antigens derived from the core protein of the human mammary epithelial mucin
|
|
US4997851A
(en)
*
|
1987-12-31 |
1991-03-05 |
Isaacs Charles E |
Antiviral and antibacterial activity of fatty acids and monoglycerides
|
|
US5466714A
(en)
*
|
1987-12-31 |
1995-11-14 |
Research Foundation For Mental Health Hygiene, Inc. |
Spermicidal and cytocidal fatty acid compositions
|
|
US5434182A
(en)
*
|
1987-12-31 |
1995-07-18 |
Isaacs; Charles E. |
Antibacterial fatty acid compositions
|
|
EP0324455A3
(en)
*
|
1988-01-15 |
1991-03-27 |
Hans O. Ribi |
Novel polymeric immunological adjuvants
|
|
WO1990003183A1
(en)
*
|
1988-09-23 |
1990-04-05 |
University Of Southern California |
Immunotherapy vaccine for melanoma tumors
|
|
FI902821A7
(fi)
*
|
1989-06-12 |
1990-12-13 |
Res Foundation For Mental Hygiene |
Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
|
|
DE4007315A1
(de)
*
|
1990-03-08 |
1991-09-12 |
Behringwerke Ag |
Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
|
|
US5091188A
(en)
*
|
1990-04-26 |
1992-02-25 |
Haynes Duncan H |
Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
|
|
US5246707A
(en)
*
|
1990-04-26 |
1993-09-21 |
Haynes Duncan H |
Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
|
|
DE69230372T2
(de)
|
1991-03-19 |
2000-06-15 |
Cytrx Corp., Norcross |
Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität
|
|
DE69229779T2
(de)
*
|
1991-04-19 |
1999-12-23 |
Lds Technologies, Inc. |
Konvertierbare mikroemulsionsverbindungen
|
|
US5688761A
(en)
*
|
1991-04-19 |
1997-11-18 |
Lds Technologies, Inc. |
Convertible microemulsion formulations
|
|
IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
|
FR2702373B1
(fr)
*
|
1993-03-08 |
1996-06-07 |
Rhone Merieux |
Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
|
|
AU685443B2
(en)
*
|
1993-03-23 |
1998-01-22 |
Smithkline Beecham Biologicals (Sa) |
Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
|
|
DE69433013T2
(de)
*
|
1993-05-27 |
2004-06-03 |
Entremed, Inc. |
Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
|
|
US5690942A
(en)
*
|
1995-06-02 |
1997-11-25 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
|
US5718904A
(en)
*
|
1995-06-02 |
1998-02-17 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
|
AU709262B2
(en)
*
|
1995-10-17 |
1999-08-26 |
Board Of Regents, The University Of Texas System |
Insoluble drug delivery
|
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
|
US5849307A
(en)
*
|
1997-03-26 |
1998-12-15 |
The Picower Institute For Medical Research |
Vaccine adjuvant
|
|
US6455323B1
(en)
|
1997-07-03 |
2002-09-24 |
Pharmacia & Upjohn Company |
Anti-bacterial methods and materials
|
|
ATE241363T1
(de)
*
|
1998-02-11 |
2003-06-15 |
Rtp Pharma Corp |
Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
|
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
|
CA2333648C
(en)
|
1998-05-29 |
2008-10-21 |
Rtp Pharma Inc. |
Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
|
|
JP4198318B2
(ja)
|
1998-08-19 |
2008-12-17 |
ヤーゴテック アクチェンゲゼルシャフト |
プロポフォールの注射可能水性分散物
|
|
GB2348203B
(en)
|
1998-11-04 |
2002-06-19 |
Imp College Innovations Ltd |
Solube beta-forms of prion proteins, methods of preparation and use
|
|
HUP0105089A3
(en)
*
|
1998-11-20 |
2002-09-30 |
Skyepharma Canada Inc |
Compositions containing the active ingredient in form dispersible phospholipid stabilized microparticles
|
|
ES2439645T3
(es)
|
1999-04-09 |
2014-01-24 |
Zoetis P&U Llc |
Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
|
|
US6790950B2
(en)
|
1999-04-09 |
2004-09-14 |
Pharmacia & Upjohn Company |
Anti-bacterial vaccine compositions
|
|
DE60020382T2
(de)
*
|
1999-09-21 |
2006-01-26 |
Skyepharma Canada Inc., Verdun |
Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
|
|
ATE300949T1
(de)
|
2000-03-17 |
2005-08-15 |
Pharmacia & Upjohn Co Llc |
Ssa inaktivierte salmonella impfstoffe
|
|
AU2001251370A1
(en)
|
2000-04-06 |
2001-10-23 |
Pharmacia And Upjohn Company |
Antimicrobial methods and materials
|
|
ES2469642T3
(es)
|
2000-04-20 |
2014-06-18 |
Jagotec Ag |
Procedimiento mejorado para partículas de fármaco insoluble en agua
|
|
US7323174B1
(en)
|
2000-06-12 |
2008-01-29 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Modulation of immune response and methods based thereon
|
|
US6634576B2
(en)
|
2000-08-31 |
2003-10-21 |
Rtp Pharma Inc. |
Milled particles
|
|
TWI354568B
(en)
*
|
2000-09-20 |
2011-12-21 |
Jagotec Ag |
Insoluble drug particle compositions with improved
|
|
US8586094B2
(en)
*
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
|
CA2440355C
(en)
*
|
2001-02-22 |
2011-03-08 |
Skyepharma Canada Inc. |
Fibrate-statin combinations with reduced fed-fasted effects
|
|
FR2824279B1
(fr)
*
|
2001-05-04 |
2004-05-28 |
Seppic Sa |
Emulsion e/h concentree
|
|
GB0112126D0
(en)
|
2001-05-18 |
2001-07-11 |
Allergene Inc |
Composition
|
|
FR2824269B1
(fr)
*
|
2001-09-03 |
2012-03-02 |
Seppic Sa |
Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
|
|
WO2004064759A2
(en)
|
2003-01-21 |
2004-08-05 |
Chiron Corporation |
Use of tryptanthrin compounds for immune potentiation
|
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
US9023366B2
(en)
|
2003-07-01 |
2015-05-05 |
The Royal Veterinary College |
Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
|
|
GB0315323D0
(en)
|
2003-07-01 |
2003-08-06 |
Royal Veterinary College |
Vaccine composition
|
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
|
US20060210590A1
(en)
|
2005-02-03 |
2006-09-21 |
Alk-Abello A/S |
Minor allergen control to increase safety of immunotherapy
|
|
US20100010217A1
(en)
*
|
2006-03-23 |
2010-01-14 |
Valiante Nicholas M |
Methods for the preparation of imidazole-containing compounds
|
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
|
US9498493B2
(en)
*
|
2007-09-27 |
2016-11-22 |
Immunovaccine Technologies Inc. |
Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
|
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
|
ES2524699T3
(es)
*
|
2008-06-05 |
2014-12-11 |
Immunovaccine Technologies Inc. |
Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
CN102300483B
(zh)
|
2010-01-29 |
2015-08-19 |
株式会社御木本 |
装饰品用卡扣
|
|
JP6227407B2
(ja)
|
2010-05-14 |
2017-11-08 |
バクスアルタ インコーポレイテッド |
Ｏｓｐａキメラおよびそのワクチンでの使用法
|
|
WO2012010291A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
|
WO2012010290A1
(en)
|
2010-07-21 |
2012-01-26 |
Athera Biotechnologies Ab |
Diagnostic and therapeutic methods and compositions for metabolic disease
|
|
US20130259892A1
(en)
|
2010-12-08 |
2013-10-03 |
Geraldine Grouard-Vogel |
Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
|
|
EP2462950A1
(en)
|
2010-12-08 |
2012-06-13 |
Neovacs |
Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
|
|
WO2012136739A1
(en)
|
2011-04-07 |
2012-10-11 |
Neovacs |
Method for treating ifnalpha related conditions
|
|
EP2508197A1
(en)
|
2011-04-07 |
2012-10-10 |
Neovacs |
Method for treating IFNalpha related conditions
|
|
SG11201401177WA
(en)
|
2011-10-06 |
2014-04-28 |
Immunovaccine Technologies Inc |
Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
|
|
GB201200259D0
(en)
|
2012-01-09 |
2012-02-22 |
Ohlin Per M |
Novel therapies
|
|
JP2015524802A
(ja)
|
2012-07-27 |
2015-08-27 |
バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ |
キメラｏｓｐａ分子を含む組成物およびその使用方法
|
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
|
EP3613764A1
(en)
|
2014-10-15 |
2020-02-26 |
Xenothera |
Composition with reduced immunogenicity
|
|
AR114911A1
(es)
|
2018-06-04 |
2020-10-28 |
Apros Therapeutics Inc |
Conjugados peptídicos de tlr7
|
|
US11364253B2
(en)
|
2018-07-02 |
2022-06-21 |
Ayuvis Research, Inc. |
Immunodulating small molecules
|
|
EP3922255A1
(en)
|
2020-06-10 |
2021-12-15 |
Prokarium Limited |
Cancer therapy
|
|
GB202009411D0
(en)
|
2020-06-19 |
2020-08-05 |
Prokarium Ltd |
Autotransporter systems
|
|
CN112807426A
(zh)
*
|
2021-01-26 |
2021-05-18 |
郭志文 |
一种基于动物疫苗的聚合物佐剂、制备方法及其应用
|
|
EP4124342A1
(en)
|
2021-07-28 |
2023-02-01 |
Prokarium Limited |
Cancer therapy with live attenuated bacteria
|
|
EP4399219A1
(en)
|
2021-09-07 |
2024-07-17 |
Université de Tours |
Coronavirus fusion protein
|
|
GB202215134D0
(en)
|
2022-10-13 |
2022-11-30 |
Prokarium Ltd |
Composition
|
|
GB202215576D0
(en)
|
2022-10-21 |
2022-12-07 |
Prokarium Ltd |
Circuit
|
|
WO2025068413A1
(en)
|
2023-09-28 |
2025-04-03 |
Prokarium Limited |
Interleukin 18 variants
|
|
WO2025068401A1
(en)
|
2023-09-28 |
2025-04-03 |
Prokarium Limited |
Interleukin 15 variant
|
|
WO2025109155A1
(en)
|
2023-11-24 |
2025-05-30 |
Prokarium Limited |
Interleukin variant
|
|
WO2025224251A1
(en)
|
2024-04-24 |
2025-10-30 |
Prokarium Limited |
Modified microorganisms
|
|
GB202405780D0
(en)
|
2024-04-24 |
2024-06-05 |
Prokarium Ltd |
Vacuole escape
|